Vol. 5 No. 2 (2025): February
Reimbursement Reviews

Abemaciclib (Verzenio)

decorative image of the issue cover

Published February 7, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses abemaciclib (Verzenio), 50 mg, 100 mg, and 150 mg oral tablets.
  • Indication: In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.